Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients.
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
Daclizumab (anti-CD25) in multiple sclerosis.
Fingolimod is a potential novel therapy for multiple sclerosis.
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment.
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Saccadic intrusions: review and update.
Neuroprotective effect of masitinib in rats with postischemic stroke.
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Physiopathological Roles of p2x Receptors in the Central Nervous System.
Safety issue puts daclizumab in doubt for MS
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis.

Pages